AAV Capsid Tropism Engineering via Peptide Toxin Display
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current viral gene delivery vectors, such as AAV, suffer from broad tropism, making it difficult to achieve specific gene delivery to targeted cell types, which is essential for therapeutic applications, especially in diseases like brain cancer where precise targeting is needed.
Innovation Solution
Engineering AAV capsids to display complex peptides from venomous animals, such as peptide toxins, which are designed to bind specific cellular receptors with high affinity, and using cell signals to ensure proper folding and compartmentalization during recombinant production, allowing for targeted gene delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If AAV capsids are engineered to display complex peptides or proteins for target specificity, then gene delivery specificity is improved, but the complexity of protein folding and assembly increases
Solution Approach 1:
The patent introduces peptide toxins as intermediary binding elements that mediate between the AAV capsid and target cell receptors. These toxins serve as specialized intermediaries with pre-evolved high-affinity binding capabilities, avoiding the need to engineer complex folding pathways from scratch. The toxin acts as a mediator that simplifies the overall system by leveraging naturally evolved binding specificity.
Solution Approach 2:
The patent changes the biochemical parameters of the capsid-displayed protein by using peptide toxins with specific properties (small size, high affinity, simple folding) rather than complex proteins like scFv or DARPIN. This parameter change - selecting toxins over other scaffolds - reduces folding complexity while maintaining or improving binding specificity.
2Reliability
If peptide toxins are used instead of scFv or DARPIN, then binding affinity and target discrimination are improved, but the challenge of proper folding in recombinant systems increases
Solution Approach 1:
The patent applies preliminary action by using peptide toxins that have already undergone natural evolution to achieve proper folding and high-affinity binding. Rather than attempting to engineer folding pathways de novo for recombinant expression, the solution leverages toxins that have already been optimized by evolution, performing the folding 'preparation' work naturally before recombinant production.
Solution Approach 2:
The patent employs small peptide toxins rather than large, complex protein scaffolds. These smaller toxin molecules are simpler to produce recombinantly, fold more readily, and can be manufactured more easily despite their challenging disulfide bond requirements. The simplicity and small size make them more tractable for recombinant expression.
3Ease of manufacture
If broad tropism AAV is used, then ease of production is maintained, but gene delivery specificity deteriorates
Solution Approach 1:
The patent applies local quality by modifying only the capsid surface properties through peptide toxin display, rather than changing the entire AAV production system. The toxin is localized to the capsid surface where it provides target-specific binding, while the rest of the AAV production machinery remains unchanged, maintaining ease of manufacture while adding specificity.
Data Source
AI summary
Methods to prepare recombinant adeno-associated virus (AAV) capsids with altered tropism and compositions having AAVs with altered tropism are provided.